The application of theranostics in different stages of prostate cancer.

Clinical Trials as Topic Humans Lutetium / therapeutic use Male Neoplasm Staging Precision Medicine / trends Prostate-Specific Antigen / therapeutic use Prostatic Neoplasms / pathology Radiopharmaceuticals / therapeutic use Radiotherapy / methods
177Lu-PSMA-617 LuPSMA PSMA targeted radionuclide therapy theranostics in prostate cancer

Journal

Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629

Informations de publication

Date de publication:
Sep 2021
Historique:
pubmed: 7 7 2021
medline: 15 12 2021
entrez: 6 7 2021
Statut: ppublish

Résumé

Despite the remarkable achievements in treating metastatic prostate cancer over the last two decades, castrate-resistant status is still considered the lethal stage of the disease. Theranostics combines a targeting compound (ligand) with a therapeutic radioisotope (radioactive particle) injected into the blood to target the cancer cells. The most studied radioligand is

Identifiants

DOI: 10.2217/fon-2020-1209 PMID: 34227404
pubmed: 34227404
doi: 10.2217/fon-2020-1209
doi:

Substances chimiques

177Lu-PSMA-617 0
Radiopharmaceuticals 0
Lutetium 5H0DOZ21UJ
Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3637-3644

Auteurs

Omar Alghazo (O)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
Prostate Cancer Theranostics & Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne 3000, Australia.
Urology Division, Clinical Sciences Department, Yarmouk University, Irbid 21163, Jordan.
ORCID: 0000-0002-1708-2888

Renu Eapen (R)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
Prostate Cancer Theranostics & Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne 3000, Australia.

Samantha Koschel (S)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.

Marcus Cumberbatch (M)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
Department of Academic Urology, University of Sheffield, Sheffield, UK.

James Buteau (J)

Prostate Cancer Theranostics & Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
Molecular Imaging & Nuclear Medicine Therapeutics, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.

Rebecca Loh (R)

Prostate Cancer Theranostics & Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.

Nathan Lawrentschuk (N)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
Prostate Cancer Theranostics & Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
Department of Urology, Royal Melbourne Hospital, Melbourne 3052, Australia.
E J Whitten Prostate Cancer Research Centre, Epworth Healthcare, Victoria 3121, Australia.

Declan G Murphy (DG)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
Prostate Cancer Theranostics & Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne 3000, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › The application of theranostics in different...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The application of theranostics in different...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Terres rares › Lanthanides › Lutétium › The application of theranostics in different...
questionsmedicales.fr › Diagnostic › Pronostic › Stadification tumorale › The application of theranostics in different...
questionsmedicales.fr › Professions de santé › Médecine › Médecine clinique › Médecine de précision › The application of theranostics in different...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Antigène spécifique de la prostate › The application of theranostics in different...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › The application of theranostics in different...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Radiopharmaceutiques › The application of theranostics in different...
questionsmedicales.fr › Thérapeutique › Radiothérapie › The application of theranostics in different...